A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors

An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of Two Forms ofGSK1363089 in Subjects With Solid Tumors

Study to compare 2 different chemical forms of GSK1363089.

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of solid tumor malignancy.
• 18 years old with ECOG of 0-1.
• female subject who is not pregnant
• Male subjects must agree to use contraception methods
• Able to swallow and retain oral medication.
• The subject will refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
• QTcB or QTcF < 470 msec.
• Bilirubin = 1.5mg/dl, AST, ALT, ALP <2X ULN in absence of malignant disease in the liver or <5X ULN in case of liver involvement by the tumor.
• Serum Creatinine <1.5mg/dL

Exclusion Inclusion:

• The subject has received anticancer treatment.
• The subject has participated in a clinical trial and has received an investigational product within 21 days.
• The subject has known brain metastases.
• The subject has uncontrolled intercurrent illness.
• History of sensitivity to any of the study medications, or components.
• The subject is known to be positive for the human immunodeficiency virus (HIV).
• Subjects who have had partial or complete gastrectomy.
• Pregnant females as determined by positive ß-hCG test at screening or prior to dosing.
• Lactating females.
• Unwillingness or inability to follow the procedures outlined in the protocol.